Nausea on Mounjaro (tirzepatide for T2D): Week-by-Week Timeline of What to Expect

What actually sets the week-by-week pattern

Mounjaro is a once-weekly subcutaneous injection that activates both GIP and GLP-1 receptors, approved to improve blood sugar in adults and in children 10 years and older with type 2 diabetes [1]. It starts at 2.5 mg once weekly, and the label raises the dose in 2.5 mg steps only after at least 4 weeks on the current dose, and only if more glycemic control is needed [1]. The maximum is 15 mg weekly in adults and 10 mg weekly in patients 10 years and older [1]. The label says to follow the starting dosage and escalation schedule to reduce the risk of gastrointestinal adverse reactions [1].

At the fastest pace the label permits, the calendar runs like this: 2.5 mg for weeks 1 to 4, 5 mg from week 5, 7.5 mg from week 9, 10 mg from week 13, 12.5 mg from week 17 and 15 mg from week 21 [1]. The label ties each increase to whether more glycemic control is needed [1], so two patients in the same calendar week can be on different doses.

The dose-by-dose numbers

The label's main adverse reaction table pools two placebo-controlled trials in adults with type 2 diabetes, SURPASS-1 (tirzepatide alone) and SURPASS-5 (tirzepatide added to basal insulin), and covers 718 patients treated with Mounjaro for a mean of 36.6 weeks [1]. Nausea was reported by 4% of the 235 patients on placebo, 12% of the 237 on 5 mg, 15% of the 240 on 10 mg and 18% of the 241 on 15 mg [1]. Diarrhea ran 9%, 12%, 13% and 17%, vomiting 2%, 5%, 5% and 9%, and decreased appetite 1%, 5%, 10% and 11% across the same arms [1].

Gastrointestinal reactions of any kind were reported by 20.4% of placebo patients and by 37.1%, 39.6% and 43.6% of those on 5, 10 and 15 mg [1]. Treatment was stopped for a GI reaction by 0.4% on placebo versus 3.0%, 5.4% and 6.6% [1], and severe GI reactions were reported by 0.9% on placebo versus 1.3%, 0.4% and 1.2% [1].

These are rates across a whole trial, not rates for a given week. The sections below pair the label's titration intervals with its statement about when reactions clustered.

Weeks 1 to 4: the 2.5 mg starting dose

The label's Table 1 reports rates for the 5, 10 and 15 mg arms and for placebo; it has no 2.5 mg column [1]. What the label attaches to this window is its instruction to follow the starting dosage and escalation schedule to reduce GI reactions, plus a pharmacokinetic detail: tirzepatide reaches steady state after 4 weeks of once-weekly dosing, and blood levels peak a median of 24 hours after a dose, within a range of 8 to 72 hours [1]. The label also notes that the delay in gastric emptying is largest after the first dose and diminishes over time [1].

Weeks 5 to 8: the first increase, and every step after it

The earliest the label allows an increase is the start of week 5, to 5 mg [1]. The label gives no week-by-week data on how reports changed after each increase.

The label also names initiation and escalation in its kidney warning: acute kidney injury has been reported, mostly in patients whose GI reactions led to dehydration from nausea, vomiting or diarrhea, and the label says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during dosage initiation and escalation [1].

Weeks 13 onward: 10 mg, 12.5 mg and 15 mg

At 10 mg the trial nausea rate is 15% and 5.4% stopped treatment for a GI reaction [1]. At 15 mg nausea is at its highest in the table, 18%, and GI discontinuation at its highest, 6.6% [1]. Severe GI reactions did not follow that gradient, at 1.2% on 15 mg versus 1.3% on 5 mg [1].

Not everyone reaches these doses. Increases are conditional on needing more glycemic control [1], and children 10 years and older are capped at 10 mg weekly [1].

What the label flags besides nausea

• Pancreatitis. The label describes persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting, and says to discontinue Mounjaro if pancreatitis is suspected [1].
• Dehydration and kidney injury. Postmarketing acute kidney injury, in some cases requiring hemodialysis, was mostly reported in patients whose GI reactions led to dehydration; the label says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and escalation [1].
• Gallbladder disease. Acute gallbladder disease, including gallstones, biliary colic and cholecystectomy, was reported by 0.6% of Mounjaro-treated patients and 0% of those on placebo [1].
• Gastroparesis. Mounjaro is not recommended in patients with severe gastroparesis [1].
• Low blood sugar. The risk of hypoglycemia is higher when Mounjaro is combined with insulin or a sulfonylurea, and the label suggests considering a reduction in the dose of those medicines when Mounjaro is started [1].

Injection day and missed doses

The label says to inject once weekly at any time of day, with or without meals [1]. The weekly day can be changed as long as the gap between two doses is at least 3 days (72 hours) [1]. A missed dose can be given within 4 days (96 hours); if more than 4 days have passed, the dose is skipped and the next one given on the regularly scheduled day [1].